Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · e780-e792.e7
DOI: 10.1016/j.clml.2026.03.014 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Benjamin Hebraud und 19 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France. Hauptthemen laut MEDLINE: Multiple Myeloma, Patient Reported Outcome Measures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
- Division of Hematology, Mayo Clinic, Rochester, Rochester, MN.
- Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
- Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Phoenix, AZ.
- Pfizer Inc, New York, NY. Electronic address: marco.dibonaventura@pfizer.com.
- Analysis Group, Inc, Boston, MA.
Förderung
- Pfizer Inc
Zitieren
APA
Hebraud, B., Charalampous, C., Parrondo, R., Chhabra, S., Nagaraj, M., DiBonaventura, M., Duh, M. S., Bobbili, P. J., Wang, A., Frey-Koba, S., Milce, J., Levy, M., Chafetz, L., Faucher, A., Johnson, S. M. A., Hlavacek, P., Cislo, P., Hughes, D., Nador, G., & Kumar, S. K. (2026). Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 26(6), e780-e792.e7. https://doi.org/10.1016/j.clml.2026.03.014
Vancouver
Hebraud B, Charalampous C, Parrondo R, Chhabra S, Nagaraj M, DiBonaventura M, et al. Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):e780-e792.e7. doi:10.1016/j.clml.2026.03.014
BibTeX
@article{Hebraud2026,
author = {Hebraud, Benjamin and Charalampous, Charis and Parrondo, Ricardo and Chhabra, Saurabh and Nagaraj, Madhu and DiBonaventura, Marco and Duh, Mei Sheng and Bobbili, Priyanka J and Wang, Aolin and Frey-Koba, Stephanie and Milce, Joseph and Levy, Maude and Chafetz, Lily and Faucher, Ariane and Johnson, Sarasa M A and Hlavacek, Patrick and Cislo, Paul and Hughes, David and Nador, Guido and Kumar, Shaji K},
title = {Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {6},
pages = {e780--e792.e7},
doi = {10.1016/j.clml.2026.03.014}
}
EUVIMED